Cited by 183Hormonal and reproductive studiesProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.

Testosterone Replacement Therapy in Patients with Prostate Cancer After Radical Prostatectomy

Open access

Pastuszak, Alexander W., Pearlman, Amy M., Lai, Win Shun, Godoy, Guilherme, Sathyamoorthy, Kumaran, Liu, Joceline S., Miles, Brian J., Lipshultz, Larry I., Khera, Mohit·2013·Journal of Urology

DOI 10.1016/j.juro.2013.02.002PMC PMC4544840

Open this paper in CoChat — free account

Abstract

PURPOSE: Testosterone replacement therapy in men with prostate cancer is controversial, with concern that testosterone can stimulate cancer growth. We evaluated the safety and efficacy of testosterone in hypogonadal men with prostate cancer treated with radical prostatectomy. MATERIALS AND METHODS: We performed a review of 103 hypogonadal men with prostate cancer treated with testosterone after prostatectomy (treatment group) and 49 nonhypogonadal men with cancer treated with prostatectomy (reference group). There were 77 men with low/intermediate (nonhigh) risk cancer and 26 with high risk cancer included in the analysis. All men were treated with transdermal testosterone, and serum hormone, hemoglobin, hematocrit and prostate specific antigen were evaluated for more than 36 months. RESULTS: Median (IQR) patient age in the treatment group was 61.0 years (55.0-67.0), and initial laboratory results included testosterone 261.0 ng/dl (213.0-302.0), prostate specific antigen 0.004 ng/ml (0.002-0.007), hemoglobin 14.7 gm/dl (13.3-15.5) and hematocrit 45.2% (40.4-46.1). Median followup was 27.5 months, at which time a significant increase in testosterone was observed in the treatment group. A significant increase in prostate specific antigen was observed in the high risk and nonhigh risk treatment groups with no increase in the reference group. Overall 4 and 8 cases of cancer recurrence were observed in treatment and reference groups, respectively. CONCLUSIONS: Thus, testosterone therapy is effective and, while followed by an increase in prostate specific antigen, does not appear to increase cancer recurrence rates, even in men with high risk prostate cancer. However, given the retrospective nature of this and prior studies, testosterone therapy in men with history of prostate cancer should be performed with a vigorous surveillance protocol.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.juro.2013.02.002

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate
Huggins, C., & Hodges, C. V. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,856
Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline.
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Investigation, treatment and monitoring of late-onset hypogonadism in males
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0601 · Cited by 867
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
Cookson, M. S., Aus, G., Burnett, A. L. “., Canby‐Hagino, E., D'Amico, A. V., Dmochowski, R. R., Eton, D. T., Forman, J. D., Goldenberg, S. L., Hernández, J., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2006.10.097 · Cited by 848
Adverse Events Associated With Testosterone Replacement in Middle-Aged and Older Men: A Meta-Analysis of Randomized, Placebo-Controlled Trials
Calof, O. M., Singh, A. B., Lee, M. L., Kenny, A. M., Urban, R. J., Tenover, J. L., & Bhasin, S. (2005) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/60.11.1451 · Cited by 728
Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden, E. L., & Morgentaler, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra022251 · Cited by 705
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.
Huggins, C., & Hodges, C. (2002) · Journal of Urology · doi:10.1016/s0022-5347(02)80307-x · Cited by 637
Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model and the Limits of Androgen-Dependent Growth
Morgentaler, A., & Traish, A. M. (2008) · European Urology · doi:10.1016/j.eururo.2008.09.024 · Cited by 469
Investigation, Treatment, and Monitoring of Late‐Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations
Wang, C., Nieschlag, E., Swerdloff, R. S., Behre, H. M., Hellstrom, W. J. G., Gooren, L. J., Kaufman, J., Legros, J. J., Lunenfeld, B., Morales, Á., et al. (2008) · Journal of Andrology · doi:10.2164/jandrol.108.006486 · Cited by 443
Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism: A Randomized Controlled Trial
Marks, L. S., Mazer, N. A., Mostaghel, E., Hess, D. L., Dorey, F. J., Epstein, J. I., Veltri, R. W., Makarov, D. V., Partin, A. W., Bostwick, D. G., et al. (2006) · JAMA · doi:10.1001/jama.296.19.2351 · Cited by 400

Show all 33 references

Sorted by citations

Evaluation and Management of Testosterone Deficiency: AUA Guideline
Mulhall, J. P., Trost, L. W., Brannigan, R. E., Kurtz, E. G., Redmon, J. B., Chiles, K. A., Lightner, D. J., Miner, M. M., Murad, M. H., Nelson, C. J., et al. (2018) · Journal of Urology · doi:10.1016/j.juro.2018.03.115 · Cited by 766
Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men
Lunenfeld, B., Mskhalaya, G. J., Zitzmann, M., Arver, S., Kalinchenko, S. Y., Tishova, Y. A., & Morgentaler, A. (2015) · The Aging Male · doi:10.3109/13685538.2015.1004049 · Cited by 318
A New Era of Testosterone and Prostate Cancer: From Physiology to Clinical Implications
Khera, M., Crawford, D., Morales, Á., Salonia, A., & Morgentaler, A. (2013) · European Urology · doi:10.1016/j.eururo.2013.08.015 · Cited by 166
Self-citation
The International Society for Sexual Medicine's Process of Care for the Assessment and Management of Testosterone Deficiency in Adult Men
Dean, J. D., McMahon, C. G., Guay, A. T., Morgentaler, A., Althof, S. E., Becher, E. F., Bivalacqua, T. J., Burnett, A. L. “., Buvat, J., Meliegy, A. E., et al. (2015) · The Journal of Sexual Medicine · doi:10.1111/jsm.12952 · Cited by 159
Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk
Michaud, J. E., Billups, K. L., & Partin, A. W. (2015) · Therapeutic Advances in Urology · doi:10.1177/1756287215597633 · Cited by 143
The Relationship between Total Testosterone Levels and Prostate Cancer: A Review of the Continuing Controversy
Klap, J., Schmid, M., & Loughlin, K. R. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.07.123 · Cited by 131
Testosterone Therapy in Men With Prostate Cancer
Kaplan, A. L., Hu, J. C., Morgentaler, A., Mulhall, J. P., Schulman, C. C., & Montorsi, F. (2015) · European Urology · doi:10.1016/j.eururo.2015.12.005 · Cited by 108
Predictors of sexual dysfunction incidence and remission in men
Martin, S. A., Atlantis, E., Lange, K., Taylor, A. W., O'Loughlin, P., & Wittert, G. A. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12483 · Cited by 105
Testosterone deficiency in the aging male
McBride, J. A., Carson, C. C., & Coward, R. M. (2015) · Therapeutic Advances in Urology · doi:10.1177/1756287215612961 · Cited by 109
Sexual Rehabilitation After Treatment For Prostate Cancer—Part 2: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015)
Salonia, A., Adaikan, G., Buvat, J., Carrier, S., El-Meliegy, A., Hatzimouratidis, K., McCullough, A., Morgentaler, A., Torres, L. O., & Khera, M. (2017) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.11.324 · Cited by 102
Self-citation
Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials
Trost, L. W., & Mulhall, J. P. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.04.068 · Cited by 98
Adult-Onset Hypogonadism
Khera, M., Broderick, G. A., Carson, C. C., Dobs, A. S., Faraday, M. M., Goldstein, I., Hakim, L. S., Hellstrom, W. J. G., Kacker, R., Köhler, T. S., et al. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.04.022 · Cited by 99
Self-citation
Incidence of Prostate Cancer in Hypogonadal Men Receiving Testosterone Therapy: Observations from 5-Year Median Followup of 3 Registries
Haider, A., Zitzmann, M., Doros, G. D., Hendrik Isbarn, A., Hammerer, P., & Yassin, A. A. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.06.071 · Cited by 96
Testosterone, testosterone therapy and prostate cancer
Yassin, A. A., Al‐Rumaihi, K., Alzubaidi, R. T., Alkadhi, S., & Ansari, A. A. (2019) · The Aging Male · doi:10.1080/13685538.2018.1524456 · Cited by 87
Risks of testosterone replacement therapy in men
Ramasamy, R., Osterberg, E. C., & Bernie, A. (2014) · Indian Journal of Urology · doi:10.4103/0970-1591.124197 · Cited by 92
Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results
Kacker, R., Hult, M., Francisco, I. S., Conners, W. P., Rojas, P. A., DeWolf, W. C., & Morgentaler, A. (2015) · Asian Journal of Andrology · doi:10.4103/1008-682x.160270 · Cited by 85
Testosterone Therapy in Patients with Treated and Untreated Prostate Cancer: Impact on Oncologic Outcomes
Ory, J., Flannigan, R. K., Lundeen, C. J., Huang, J. G., Pommerville, P. J., & Goldenberg, S. L. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.04.069 · Cited by 78
The practical management of testosterone deficiency in men
Aversa, A., & Morgentaler, A. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.238 · Cited by 75
Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen
Pastuszak, A. W., Gomez, L. P., Scovell, J. M., Khera, M., Lamb, D. J., & Lipshultz, L. I. (2015) · Sexual Medicine · doi:10.1002/sm2.76 · Cited by 71
Self-citation
Testosterone Replacement Therapy and Prostate Cancer Incidence
Eisenberg, M. L. (2015) · The World Journal of Men s Health · doi:10.5534/wjmh.2015.33.3.125 · Cited by 70
Long‐acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer
Balbontin, F. G., Moreno, S. A., Bley, E., Chacón, R., Silva, A., & Morgentaler, A. (2014) · British Journal of Urology · doi:10.1111/bju.12668 · Cited by 70
Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer
Pastuszak, A. W., Khanna, A., Badhiwala, N. G., Morgentaler, A., Hult, M., Conners, W. P., Sarosdy, M. F., Yang, C., Carrión, R., Lipshultz, L. I., et al. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.05.084 · Cited by 68
Self-citation
Diagnosis and Treatment of Testosterone Deficiency: Updated Recommendations From the Lisbon 2018 International Consultation for Sexual Medicine
Morgentaler, A., Traish, A. M., Hackett, G. I., Jones, T. H., & Ramasamy, R. (2019) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2019.06.003 · Cited by 67
Tadalafil for Prevention of Erectile Dysfunction After Radiotherapy for Prostate Cancer
Pisansky, T. M., Pugh, S. L., Greenberg, R. E., Pervez, N., Reed, D. R., Rosenthal, S. A., Mowat, R. B., Raben, A., Buyyounouski, M. K., Kachnic, L. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.2626 · Cited by 62
Testosterone Deficiency: A Review and Comparison of Current Guidelines
Kwong, J. C. C., Krakowsky, Y., & Grober, E. D. (2019) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.03.262 · Cited by 58
Current topics in testosterone replacement of hypogonadal men
Nieschlag, E. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.09.008 · Cited by 55
Testosterone replacement therapy reduces biochemical recurrence after radical prostatectomy
Ahlering, T. E., Huynh, L. M., Towe, M. M., See, K., Tran, J., Osann, K., el Khatib, F. M., & Yafi, F. A. (2020) · British Journal of Urology · doi:10.1111/bju.15042 · Cited by 52
The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications
Kumar, R., Sena, L. A., Denmeade, S. R., & Kachhap, S. K. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00686-y · Cited by 52
Androgens, aging, and prostate health
Welén, K., & Damber, J. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09730-z · Cited by 52
Testosterone Replacement Therapy Following the Diagnosis of Prostate Cancer: Outcomes and Utilization Trends
Kaplan, A. L., Trinh, Q., Sun, M., Carter, S. C., Nguyen, P. L., Shih, Y. T., Marks, L. S., & Hu, J. C. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12429 · Cited by 49
The Effect of Testosterone Replacement Therapy on Prostate-Specific Antigen (PSA) Levels in Men Being Treated for Hypogonadism
Kang, D., & Li, H. (2015) · Medicine · doi:10.1097/md.0000000000000410 · Cited by 47
Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer
Lenfant, L., Léon, P., Cancel‐Tassin, G., Audouin, M., Staerman, F., Morgan Rouprêt, A., & Cussenot, O. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.04.008 · Cited by 47
An update on male hypogonadism therapy
Surampudi, P. N., Swerdloff, R. S., & Wang, C. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.913022 · Cited by 46
Evolution of Guidelines for Testosterone Replacement Therapy
Park, H. J., Ahn, S. T., & Moon, D. G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030410 · Cited by 44
Guidelines for Sexual Health Care for Prostate Cancer Patients: Recommendations of an International Panel
Wittmann, D. A., Mehta, A., McCaughan, E., Faraday, M. M., Duby, A. A., Matthew, A., Incrocci, L., Burnett, A. L. “., Nelson, C. J., Elliott, S., et al. (2022) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2022.08.197 · Cited by 48
Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis
Parizi, M. K., Abufaraj, M. M., Fajković, H., Kimura, S., Iwata, T., D’Andrea, D., Karakiewicz, P. I., & Shariat, S. F. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.06.007 · Cited by 44
Diagnosis and management of testosterone deficiency
Coward, R. M., McBride, J., & Carson, C. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.143317 · Cited by 45
Potential application of testosterone replacement therapy as treatment for obesity and type 2 diabetes in men
Fink, J. E., Matsumoto, M., & Tamura, Y. (2018) · Steroids · doi:10.1016/j.steroids.2018.08.002 · Cited by 42
The Current Landscape of Pharmacotherapies for Sarcopenia
Bahat, G., & Özkök, S. (2024) · Drugs & Aging · doi:10.1007/s40266-023-01093-7 · Cited by 41
Late-onset Hypogonadism and Testosterone Therapy – A Summary of Guidelines from the American Urological Association and the European Association of Urology
Fode, M. M., Salonia, A., Minhas, S., Burnett, A. L. “., & Shindel, A. W. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.02.021 · Cited by 36
Controversies and Advances With Testosterone Therapy: A 40-Year Perspective
Morgentaler, A. (2015) · Urology · doi:10.1016/j.urology.2015.11.034 · Cited by 35
Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations
Morgentaler, A., & Conners, W. P. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.148067 · Cited by 35
Human chorionic gonadotropin treatment: a viable option for management of secondary hypogonadism and male infertility
Fink, J. E., Schoenfeld, B. J., Hackney, A. C., Maekawa, T., & Horie, S. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1863783 · Cited by 27
Testosterone Replacement Therapy: The Emperor's New Clothes
Sansone, A., Sansone, M., Lenzi, A., & Romanelli, F. (2016) · Rejuvenation Research · doi:10.1089/rej.2016.1818 · Cited by 26
Testosterone Replacement Therapy in Men with Prostate Cancer: A Time-Varying Analysis
Kaplan, A. L., Lenis, A. T., Shah, A., Rajfer, J., & Hu, J. C. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12768 · Cited by 26
The Role of Testosterone Therapy in the Setting of Prostate Cancer
Rodríguez, K. M. G., Pastuszak, A. W., & Khera, M. (2018) · Current Urology Reports · doi:10.1007/s11934-018-0812-1 · Cited by 25
Self-citation
Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth
Krakowsky, Y., & Morgentaler, A. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.06.008 · Cited by 25
Controversies in Testosterone Therapy
Twitchell, D. K., Pastuszak, A. W., & Khera, M. (2020) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2020.09.004 · Cited by 27
Self-citation
Testosterone therapy and prostate cancer—safety concerns are well founded
Klotz, L. H. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2014.338 · Cited by 24
Andropause or Male Menopause? Rationale for Testosterone Replacement Therapy in Older Men with Low Testosterone Levels
Cunningham, G. R. (2013) · Endocrine Practice · doi:10.4158/ep13217.ra · Cited by 24
Testosterone therapy and prostate cancer
Pastuszak, A. W., Rodríguez, K. M. G., Nguyen, T. M., & Khera, M. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.08.17 · Cited by 23
Self-citation
Testosterone Therapy for High-risk Prostate Cancer Survivors: A Systematic Review and Meta-analysis
Teeling, F., Raison, N. T. J., Shabbir, M., Yap, T., Prokar Dasgupta, A., & Ahmed, K. (2018) · Urology · doi:10.1016/j.urology.2018.07.064 · Cited by 23
Irrational Exuberance in Testosterone Prescribing: When Will the Bubble Burst?
Handelsman, D. J. (2015) · Medical Care · doi:10.1097/mlr.0000000000000416 · Cited by 22
Testosterone Therapy Among Prostate Cancer Survivors
Nguyen, T. M., & Pastuszak, A. W. (2016) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2016.06.005 · Cited by 22
Self-citation
Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials
Nabid, A., Carrier, N., Vigneault, É., Martin, A., Bahary, J.-P., Nguyen, T. V., Vavassis, P., Vass, S., Brassard, M.-A., Bahoric, B., et al. (2024) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110256 · Cited by 22
Androgens and prostate disease
Page, S., & Cooper, L. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122361 · Cited by 22
Testosterone deficiency syndrome: benefits, risks, and realities associated with testosterone replacement therapy.
Hassan, J., & Barkin, J. (2016) · PubMed · Cited by 21
Testosterone therapy and risk of breast cancer development: a systematic review
Ray, A. W., Fernstrum, A. J., Mahran, A., & Thirumavalavan, N. (2020) · Current Opinion in Urology · doi:10.1097/mou.0000000000000763 · Cited by 21
Shifting the Paradigm of Testosterone Replacement Therapy in Prostate Cancer
Bell, M. A., Campbell, J. D., Joice, G. A., Sopko, N. A., & Burnett, A. L. “. (2018) · The World Journal of Men s Health · doi:10.5534/wjmh.170007 · Cited by 20
Elevated Dihydrotestosterone is Associated with Testosterone Induced Erythrocytosis
Aghazadeh, M. A., Pastuszak, A. W., Johnson, W. G., McIntyre, M. G., Hsieh, T., & Lipshultz, L. I. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.01.038 · Cited by 19
Self-citation
Current management of erectile dysfunction in prostate cancer survivors
Sherer, B. A., & Levine, L. A. (2014) · Current Opinion in Urology · doi:10.1097/mou.0000000000000072 · Cited by 18
Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024)
Khera, M., Torres, L. O., Grober, E. D., Morgentaler, A., Miner, M. M., Jones, T. H., Mills, J. N., & Salonia, A. (2025) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeaf036 · Cited by 21
Self-citation
Prostate Risk and Monitoring During Testosterone Replacement Therapy
Bhasin, S., & Thompson, I. M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae334 · Cited by 17
Testosterone Supplementation Therapy in the Treatment of Patients with Metabolic Syndrome
Kovac, J. R., Pastuszak, A. W., Lamb, D. J., & Lipshultz, L. I. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2843 · Cited by 18
Self-citation
Testosterone Therapy After Prostate Cancer Treatment: A Review of Literature
Natale, C., Carlos, C., Hong, J., Khera, M., Baum, N. H., & Raheem, O. A. (2021) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2020.12.003 · Cited by 17
Self-citation
A survey of Canadian urologists’ opinions and prescribing patterns of testosterone replacement therapy in men on active surveillance for low-risk prostate cancer
Millar, A. C., Elterman, D., Goldenberg, L., Asseldonk, B. V., Curtis, A. F., & Jarvi, K. A. (2016) · Canadian Urological Association Journal · doi:10.5489/cuaj.3608 · Cited by 16
Low Serum Testosterone is Present in Nearly Half of Men Undergoing Artificial Urinary Sphincter Placement
McKibben, M. J., Fuentes, J. L., Shakir, N. A., Fuchs, J. S., Viers, B. R., Pagliara, T. J., Hofer, M. D., Scott, J. M., & Morey, A. F. (2018) · Urology · doi:10.1016/j.urology.2018.04.018 · Cited by 16
Safety of testosterone therapy in men with prostate cancer
Morgentaler, A., & Caliber, M. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1666103 · Cited by 15
Testosterone Replacement Therapy in Men with Untreated or Treated Prostate Cancer: Do We Have Enough Evidences?
Kim, M., Byun, S., & Hong, S. K. (2020) · The World Journal of Men s Health · doi:10.5534/wjmh.190158 · Cited by 15
Oncological safety and functional outcomes of testosterone replacement therapy in symptomatic adult-onset hypogonadal prostate cancer patients following robot-assisted radical prostatectomy
Shahine, H., Zanaty, M., Zakaria, A. S., Nguyen, D., Couture, F., Sadri, I., Schwartz, R., Arezki, A., Elterman, D., El‐Hakim, A., et al. (2020) · World Journal of Urology · doi:10.1007/s00345-020-03475-7 · Cited by 15
Recommandations pratiques pour la prise en charge du déficit en testostérone
Burte, C., Lejeune, H., Faix, A., Desvaux, P., Almont, T., Cuzin, B., & Huyghe, É. (2021) · The French Journal of Urology · doi:10.1016/j.purol.2020.09.026 · Cited by 15
Serum Testosterone Level, Testosterone Replacement Treatment, and Prostate Cancer
Atan, A., Tuncel, A., Yeşil, S., & Balbay, D. (2013) · Advances in Urology · doi:10.1155/2013/275945 · Cited by 15
Late‐onset hypogonadism: Prostate safety
Miranda, E., & Torres, L. O. (2020) · Andrology · doi:10.1111/andr.12772 · Cited by 16
When and When Not To Use Testosterone for Palliation in Cancer Care
Dev, R., Bruera, E. D., & Fabbro, E. D. (2014) · Current Oncology Reports · doi:10.1007/s11912-014-0378-0 · Cited by 16
Testosterone and Prostate Safety
Schulman, C., & Morgentaler, A. (2014) · Springer eBooks · doi:10.1007/978-3-662-45018-5_11 · Cited by 14
The safety of testosterone supplementation therapy in prostate cancer
Dupree, J. M., Langille, G. M., Khera, M., & Lipshultz, L. I. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.163 · Cited by 14
Self-citation
Testosterone replacement therapy and the risk of prostate cancer
Wang, R., Warburton, D., Hobaugh, C., Wang, G., & Lin, H. (2015) · Asian Journal of Andrology · doi:10.4103/1008-682x.150841 · Cited by 14
Testosterone Therapy and Prostate Cancer
Davidson, E., & Morgentaler, A. (2016) · Urologic Clinics of North America · doi:10.1016/j.ucl.2016.01.007 · Cited by 13
Testosterone analysis in prostate cancer patients
van Winden, L. J., & van Rossum, H. H. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2021.07.007 · Cited by 13
Testosterone deficiency and replacement: Myths and realities
Grober, E. D. (2014) · Canadian Urological Association Journal · doi:10.5489/cuaj.2309 · Cited by 14
The role of androgen therapy in prostate cancer: from testosterone replacement therapy to bipolar androgen therapy
Xie, T., Song, X., Wang, C., Yu, Y., Wang, J., Chen, Z., & Zhao, S. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.034 · Cited by 12
Testosterone Therapy on Active Surveillance and Following Definitive Treatment for Prostate Cancer
Golla, V., & Kaplan, A. L. (2017) · Current Urology Reports · doi:10.1007/s11934-017-0695-6 · Cited by 12
Testosterone Therapy in Men with Biochemical Recurrence and Metastatic Prostate Cancer: Initial Observations
Morgentaler, A., Abello, A., & Bubley, G. J. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2021.0001 · Cited by 12
Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States
Chen, T., Li, S., & Eisenberg, M. L. (2021) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2021.06.007 · Cited by 12
Adult-onset hypogonadism: evaluation and role of testosterone replacement therapy
Davidiuk, A. J., & Broderick, G. A. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.09.02 · Cited by 13
Regulate and Communicate: Associations between Emotion Regulation and Sexual Communication among Men with Hypoactive Sexual Desire Disorder and their Partners
Wang, G. A., Corsini‐Munt, S., Dubé, J. P., McClung, E., & Rosen, N. O. (2022) · The Journal of Sex Research · doi:10.1080/00224499.2022.2092588 · Cited by 11
Evaluation of sexual function after robot‐assisted radical prostatectomy: A farewell to IIEF questionnaire
Shiraishi, K. (2023) · International Journal of Urology · doi:10.1111/iju.15264 · Cited by 10
To Treat or Not to Treat with Testosterone Replacement Therapy: a Contemporary Review of Management of Late-Onset Hypogonadism and Critical Issues Related to Prostate Cancer
Kava, B. (2014) · Current Urology Reports · doi:10.1007/s11934-014-0422-5 · Cited by 10
Bipolar Androgen Therapy: When Excess Fuel Extinguishes the Fire
Nabavi, N., Mahdavi, S. R., Ardalan, M. A., Chamanara, M., Mosaed, R., Lara, A., Bastos, D. A., Harsini, S., Askari, E., Velho, P. I., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11072084 · Cited by 11
Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pARser81 and CDK1 signaling: biological implications for men treated with testosterone replacement therapy
Gravina, G. L., Marampon, F., Sanità, P., Festuccia, C., Forcella, C., Scarsella, L., Jitariuc, A., Vetuschi, A., Sferra, R., Colapietro, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22776 · Cited by 11
The effect of different administrations of testosterone therapy on adverse prostate events: A Bayesian network meta-analysis
Zeng, B., Qiu, S., Xiong, X., Su, X., Zhang, Z., Wei, Q., & Yang, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1009900 · Cited by 9
Effects of Testosterone on Benign and Malignant Conditions of the Prostate
Herati, A. S., Kohn, T. P., Butler, P. R., & Lipshultz, L. I. (2017) · Current Sexual Health Reports · doi:10.1007/s11930-017-0104-7 · Cited by 9
Self-citation
Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism
Gray, H., Seltzer, J., & Talbert, R. L. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140128 · Cited by 8
Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review
Kadomoto, S., Shigehara, K., Iwamoto, H., Yaegashi, H., Izumi, K., Kadono, Y., & Mizokami, A. (2019) · The World Journal of Men s Health · doi:10.5534/wjmh.180130 · Cited by 8
Additional value of the ratio of serum total testosterone to total prostate-specific antigen in the diagnosis of prostate cancer in a Chinese population
Xu, L., Hu, X., Zhu, Y., Lu, J., Xu, Y., Wang, G., & Guo, J. (2017) · Andrologia · doi:10.1111/and.12872 · Cited by 8
Testosterone and Men's Health
Anaissie, J. E., Pastuszak, A. W., & Khera, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816665-9.00012-3 · Cited by 8
Self-citation
Current state of practice regarding testosterone supplementation therapy in men with prostate cancer
Kovac, J. R., Pan, M. M., Lipshultz, L. I., & Lamb, D. J. (2014) · Steroids · doi:10.1016/j.steroids.2014.07.004 · Cited by 7
Self-citation
Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy
Shoskes, D. A., Barazani, Y., Fareed, K., & Sabanegh, E. (2015) · International braz j urol · doi:10.1590/s1677-5538.ibju.2014.0528 · Cited by 6
Update on Testosterone Replacement Therapy in Hypogonadal Men
Leung, K. M. Y. B., Alrabeeah, K. A., & Carrier, S. (2015) · Current Urology Reports · doi:10.1007/s11934-015-0523-9 · Cited by 6
Challenges to treat hypogonadism in prostate cancer patients: implications for endocrinologists, urologists and radiotherapists.
Gravina, G. L., Sante, S. D., Limoncin, E., Mollaioli, D., Ciocca, G., Carosa, E., Sanità, P., Cesare, E. D., Lenzi, A., & Jannini, E. A. (2015) · PubMed Central · doi:10.3978/j.issn.2223-4683.2015.04.01 · Cited by 6

Authors: Pastuszak, A. W., Pearlman, A. M., Lai, W. S., Godoy, G., Sathyamoorthy, K., Liu, J. S., Miles, B. J., Lipshultz, L. I., & Khera, M.
Affiliations: Baylor College of Medicine (US)
University of Pennsylvania (US)
Northwestern University (US)
Houston Methodist (US)
ORCID: Pastuszak, Alexander W.
Pearlman, Amy M.
Godoy, Guilherme
Miles, Brian J.
Lipshultz, Larry I.
Khera, Mohit
Venue: Journal of Urology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2013-08
Volume: 190
Issue: 2
Pages: 639-644
ISSN: 0022-5347 (ISSN-L)
1527-3792
DOI: 10.1016/j.juro.2013.02.002
PMC: PMC4544840
OpenAlex: W2091445581
Cited by: 183
References: 33
Citations by year: 2026: 6 · 2025: 12 · 2024: 9 · 2023: 9 · 2022: 18 · 2021: 6 · 2020: 15 · 2019: 15 · 2018: 11 · 2017: 10 · 2016: 13 · 2015: 27 · 2014: 26 · 2013: 6
FWCI: 18.92
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Journal of Urology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (K23CA160664)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords: testosterone replacement therapy, prostate cancer, radical prostatectomy, hypogonadism, transdermal testosterone, prostate-specific antigen, tumor recurrence, high-risk prostate cancer, low-risk prostate cancer, hemoglobin, hematocrit, hormone therapy safety
MeSH terms: Aged, Hematocrit, Hemoglobins, Humans, Hypogonadism, Male, Middle Aged, Prostatectomy, Prostatic Neoplasms, Retrospective Studies, Testosterone, Linear Models, Treatment Outcome, Prostate-Specific Antigen, Statistics, Nonparametric, Hormone Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Testosterone Replacement Therapy in Patients with Prostate Cancer After Radical Prostatectomy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks